Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
61.8M
-
Number of holders
-
104
-
Total 13F shares, excl. options
-
61M
-
Shares change
-
+11.2M
-
Total reported value, excl. options
-
$423M
-
Value change
-
+$79.1M
-
Put/Call ratio
-
0.06
-
Number of buys
-
64
-
Number of sells
-
-28
-
Price
-
$6.94
Significant Holders of Monte Rosa Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GLUE) as of Q4 2024
119 filings reported holding GLUE - Monte Rosa Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q4 2024.
Monte Rosa Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GLUE) has 104 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 61M shares
of 61.8M outstanding shares and own 98.71% of the company stock.
Largest 10 shareholders include NEA Management Company, LLC (7.69M shares), PRICE T ROWE ASSOCIATES INC /MD/ (7.12M shares), Versant Venture Management, LLC (5.65M shares), FMR LLC (5.55M shares), BAKER BROS. ADVISORS LP (4.92M shares), Avoro Capital Advisors LLC (4.35M shares), BlackRock, Inc. (3.84M shares), VANGUARD GROUP INC (3.16M shares), BVF INC/IL (2.76M shares), and MORGAN STANLEY (2.26M shares).
This table shows the top 104 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.